Holen Sie sich die Stockscreener-App
8.615
7.17%
-0.655
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt AVXL?
Forum
Prognose
Aktiensplit
Anavex Life Sciences Corporation Aktie (AVXL) Neueste Nachrichten
How strong is Anavex Life Sciences Corp. stock revenue growthWeekly Investment Recap & Weekly High Conviction Ideas - newser.com
Detecting price anomalies in Anavex Life Sciences Corp. with AIJuly 2025 Reactions & Fast Exit/Entry Strategy Plans - newser.com
Real time breakdown of Anavex Life Sciences Corp. stock performanceMarket Sentiment Report & Fast Entry High Yield Stock Tips - newser.com
Can trapped investors hope for a rebound in Anavex Life Sciences Corp.July 2025 Sentiment & Long-Term Safe Investment Plans - newser.com
How Anavex Life Sciences Corp. stock valuations compare to rivalsJuly 2025 Update & AI Powered Market Entry Strategies - newser.com
Heatmap analysis for Anavex Life Sciences Corp. and competitorsWeekly Stock Summary & Safe Entry Zone Identification - newser.com
Anavex Life Sciences Announces Presentation at the 35th Alzheimer Europe Conference ‘Connecting Science and Communities: The Future of Dementia Care’ - The Manila Times
Anavex Life Sciences Corp. Announces Oral Presentation on Alzheimer's Disease Care at Alzheimer Europe Conference - Quiver Quantitative
Oral Blarcamesine Presented at 35th Alzheimer Europe — Anavex Highlights ANAVEX®2-73-AD-004 IIb/III - Stock Titan
Will Anavex Life Sciences Corp. (12X1) stock keep high P E multiplesJuly 2025 Analyst Calls & Growth Focused Investment Plans - newser.com
Is Anavex Life Sciences Corp. (12X1) stock testing key supportWeekly Trade Report & Community Verified Trade Alerts - newser.com
Anavex Life Sciences (NASDAQ:AVXL) Given "Sell (D-)" Rating at Weiss Ratings - MarketBeat
Anavex Life Sciences (NASDAQ:AVXL) Receives Buy Rating from HC Wainwright - MarketBeat
HC Wainwright & Co. Reiterates Anavex Life Sciences (AVXL) Buy Recommendation - Nasdaq
Anavex Life Sciences stock rating reiterated at Buy by H.C. Wainwright - Investing.com
How Anavex Life Sciences Corp. stock reacts to global recession fearsBreakout Watch & Low Drawdown Momentum Ideas - newser.com
Long term hold vs stop loss in Anavex Life Sciences Corp.Analyst Downgrade & Community Consensus Stock Picks - newser.com
Tools to monitor Anavex Life Sciences Corp. recovery probabilityEarnings Risk Report & Advanced Technical Signal Analysis - newser.com
Anavex Life Sciences (NASDAQ:AVXL) Trading Up 8.7%Should You Buy? - MarketBeat
Anavex Life Sciences (Nasdaq:AVXL) Reports Positive Phase 2 Results for ANAVEX®3-71 in Schizophrenia - Kalkine Media
D. Boral Capital Maintains Anavex Life Sciences (AVXL) Buy Recommendation - Nasdaq
Is Anavex Life Sciences Corp a good long term investmentBollinger Bands Signals & Free Phenomenal Capital Appreciation - earlytimes.in
Anavex: ANAVEX 3-71 Could Potentially Offer Disease-Modifying Effects For Schizophrenia - Seeking Alpha
Anavex Life Sciences (NASDAQ:AVXL) Sees Strong Trading VolumeWhat's Next? - MarketBeat
Anavex Life Sciences (AVXL): Analyst Reaffirms "Buy" Rating | AV - GuruFocus
Anavex Life Sciences Stock Just Shot Up 7% Today – Here’s An Important Update - Stocktwits
Anavex Life Sciences (AVXL) Shares Rise on Positive Trial Result - GuruFocus
Anavex Life Sciences Reports Positive Phase 2 Results for ANAVEX®3-71 in Schizophrenia Clinical Study Achieving Safety and Tolerability Endpoints - Quiver Quantitative
Anavex Life Sciences Announces Successful Development of Once-Daily Oral Tablet Formulation for the ANAVEX®3-71 Program - The Manila Times
Anavex Life Sciences Announces Positive Topline Results from Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia - The Manila Times
Anavex Life Sciences stock rises after positive schizophrenia drug trial - Investing.com
Anavex Develops Once-Daily Tablet for ANAVEX3-71 in Phase 1b Trial | AVXL Stock News - Stock Titan
Novel Schizophrenia Drug ANAVEX3-71 Shows Promise: Safe Profile and Reduced Brain Inflammation Markers - Stock Titan
Anavex Life Sciences (NASDAQ:AVXL) Receives “Buy” Rating from D. Boral Capital - Defense World
Alzheimer’s Disease Market: Epidemiology, Therapies, and Key Players | Anavex Life Sciences Corp., TauRx Therapeutics Ltd, BioVie Inc., AriBio Co., Ltd., Novo Nordisk A/S, AgeneBio, Neurim Pharmaceuti - Barchart.com
Anavex Life Sciences (NASDAQ:AVXL) Earns "Buy" Rating from D. Boral Capital - MarketBeat
Alzheimer's Disease Market: Epidemiology, Therapies, And Key Players Anavex Life Sciences Corp., Taurx Therapeutics Ltd, Biovie Inc., Aribio Co., Ltd., Novo Nordisk A/S, Agenebio, Neurim Pharmaceuti - Menafn.com
Anavex Life Sciences Announces Publication of Oral Blarcamesine Describing a New Class of Clinical Precision Medicine from Phase IIb/III Alzheimer’s Disease Trial - markets.businessinsider.com
Anavex Life Sciences Announces Publication of Oral Blarcamesine Describing a New Class of Clinical Precision Medicine from Phase IIb/III Alzheimer's Disease Trial - Investing News Network
Anavex Life Sciences Announces Publication of Oral - GlobeNewswire
70% Success Rate: Anavex's Once-Daily Oral Alzheimer's Drug Shows Breakthrough Results in Late-Stage Trial - Stock Titan
Why millennials buy Anavex Life Sciences Corp. (12X1) stockJuly 2025 PostEarnings & Daily Price Action Insights - newser.com
How to recover losses in Anavex Life Sciences Corp. stockJuly 2025 Drop Watch & Safe Entry Point Identification - newser.com
Real time pattern detection on Anavex Life Sciences Corp. stockMarket Volume Summary & Target Return Focused Stock Picks - newser.com
What drives PRCT stock priceMarket Sentiment Shifts & These 3 Stocks Could Change Your Portfolio - earlytimes.in
What drives Anavex Life Sciences Corp stock priceOptions Trading Strategies & Minimal Capital Growth Plans - earlytimes.in
What analysts say about Anavex Life Sciences Corp stockEquity Performance Review & Stocks With 200% Upside Potential - Early Times
How Anavex Life Sciences Corp. (12X1) stock trades pre earningsJuly 2025 Gainers & Free Safe Entry Trade Signal Reports - newser.com
H.C. Wainwright Reiterates Its ‘Buy’ Rating on Anavex Life Sciences Corp. (AVXL) with a $42 Price Target - Insider Monkey
Anavex Life Sciences Corp. $AVXL Shares Sold by Goldman Sachs Group Inc. - MarketBeat
Published on: 2025-09-22 05:58:42 - newser.com
1.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):